{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.2","upperLimit":"76.9","value":"65.7"},{"groupId":"OG001","lowerLimit":"34.2","upperLimit":"61.4","value":"48.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"To compare the two-year event-free survival (EFS) of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine.\n\nEFS event = same definition as PFS with non-protocol treatment also considered an event","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.\n\n\\>\n\n\\> carmustine: Given IV\n\n\\>\n\n\\> thiotepa: Given IV\n\n\\>\n\n\\> stem cell transplant\n\n\\>\n\n\\> G-CSF","id":"OG000","title":"Arm I"},{"description":"Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.\n\n\\>\n\n\\> cytarabine: Given IV\n\n\\>\n\n\\> etoposide: Given IV\n\n\\>\n\n\\> G-CSF","id":"OG001","title":"Arm II"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Event Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants w/out event"}